Ronacaleret
Ronacaleret (SB 751689) is an orally active, potent, and selective calcium-sensing receptor (CaSR) antagonist that stimulates endogenous parathyroid hormone release from the parathyroid glands. Ronacaleret (SB 751689) is used for the study of postmenopausal osteoporosis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 753449-67-1
- Fòrmula: C25H31F2NO4
- Peso molecular:447.51
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-70037
Cinacalcet
-
HY-70037A
Cinacalcet hydrochloride
-
HY-22009A
Strontium chloride,anhydrous grade,99.99% metals basis
-
HY-10171
NPS-2143 hydrochloride
-
HY-P1955A
Etelcalcetide hydrochloride
-
HY-122819
Calindol hydrochloride
-
HY-17613
Evocalcet
-
HY-15105
SB-423562
-
HY-14401
Encaleret
-
HY-70037AR
Cinacalcet hydrochloride (Standard)
-
HY-107773
GSK3004774
-
HY-117851
AC-265347
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
146 nM
Compound: Ronacaleret
|
Negative allosteric modulator activity at human recombinant calcium sensing receptor expressed in HEK cells
Negative allosteric modulator activity at human recombinant calcium sensing receptor expressed in HEK cells
|
[PMID: 19442519] |
| HEK293 | IC50 |
320 nM
Compound: Ronacaleret
|
Negative allosteric modulator activity at rat calcium sensing receptor expressed in HEK cells
Negative allosteric modulator activity at rat calcium sensing receptor expressed in HEK cells
|
[PMID: 19442519] |
Ronacaleret inhibits OATP1B1 (IC50 = 11 μM) and OATP2B1 (IC50 = 12 μM) in vitro, whereas it does not inhibit BCRP[3].
Ronacaleret is shown to inhibit the OATP1B1- and OATP1B3-mediated uptake of the probe substrate estradiol-glucuronide with relatively low potency (IC50 values of 11 and 60 μM, respectively)[3].
Ronacaleret inhibits OATP2B1-mediated rosuvastatin transport at pH 7.4 and pH 6.0, with IC50 values of 16 and 12 μM, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:7-week-old Wistar rats[2].
-
Dosage:3 mg/kg/day (dissolved in 10% β-cyclodextrin solution).
-
Administration:Administered by an osmotic pump that was implanted subcutaneously.
-
Result:Increased renal expression of klotho in a dose-dependent manner.
Decreased serum phosphate and FGF23 with the increased fractional excretion of phosphate without changes in serum calcium.
Appeared to similarly protect podocytes.
Reduced FGF23 and because FGF23 enhanced klotho expression.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 753449-67-1
-
Peso molecular 447.51
-
Fòrmula C25H31F2NO4
-
SMILES
O=C(O)CCC1=CC(F)=C(F)C(OC[C@H](O)CNC(C)(C)CC2CC3=C(C=CC=C3)C2)=C1
-
Synonyms
SB 751689
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. György Szabó, et al. Discovery of dihydropyrazino-benzimidazole derivatives as metabotropic glutamate receptor-2 (mGluR2) positive allosteric modulators (PAMs). Eur J Med Chem. 2020 Jan 15:186:111881. [Content Brief]
[2]. Tsuneo Takenaka , et al. Antialbuminuric actions of calcilytics in the remnant kidney. Am J Physiol Renal Physiol. 2015 Aug 1;309(3):F216-26. [Content Brief]
[3]. Marta Johnson, et al. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin. Drug Metab Dispos. 2017 Jan;45(1):27-34. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ronacaleret Related Classifications
HY-14752 Related Classifications
Powered by Bioz